Acrux (ASX:ACR) — Material Events
ASX:ACR · 13 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Acrux Accelerates Female Testosterone Development with $5M Revenue Surge and FDA Phase III ClarityMedium
Acrux reports strong revenue growth, FDA Phase III pathway for Female Testosterone, and $1.6M funding
31 July 2026
·Quarterly Activities Report and Appendix 4C
·85
Acrux Narrows FY26 Loss 90% as Female Testosterone Development Gains MomentumMedium
Acrux FY26 revenue up 46%, net loss narrows 90%, advances Female Testosterone MDTS development
26 Aug 2026
·Annual Financial Report and Results Announcement
·85
Acrux Advances Female Testosterone Therapy with Phase III Trial and $21 Billion Market PotentialMedium
Acrux presents Female Testosterone MDTS development and market opportunity at Bioshares Biotech Summit
6 Aug 2026
·Investor Presentation
·80
Acrux Unveils 449% Growth in Generics Licensing and New R&D Focus at 2025 AGMMedium
Acrux reports strong generic portfolio growth and strategic focus on new R&D at 2025 AGM
25 Nov 2025
·Annual General Meeting Presentation
·75
Acrux Secures AUD 5.4 Million Milestone Deal for Lenzetto to Address Australian Menopause Therapy ShortageMedium
Acrux secures AUD 5.4 million milestone deal for Lenzetto® to address Australian menopause therapy shortage
28 May 2026
·Licensing Agreement Amendment
·75
Acrux Boosts US Footprint and Eyes Hormone Therapy Growth Amid Portfolio ShiftMedium
Acrux reports revenue growth, portfolio expansion, and strategic pivot to HRT with increased cash reserves
29 Jan 2026
·Quarterly Activities Report and Appendix 4C
·75
Acrux Surpasses Prior Year Profit Share in September QuarterMedium
Acrux posts strong quarterly revenue growth and repays R&D advances in September 2025 quarter
31 Oct 2025
·Quarterly Activities Report and Appendix 4C
·75
Acrux Secures $1.6 Million Placement to Back Female Testosterone TrialsMedium
Acrux raises $1.6 million via discounted share placement with attaching options
11 May 2026
·Capital Raising
·70
Acrux Secures AUD 5.4 Million Milestone Deal for Lenzetto in AustraliaMedium
Acrux licenses Lenzetto® for Australia with AUD 5.4 million milestone deal
29 May 2026
·Licensing Update
·70
Acrux Divests US Rights for Prilocaine/Lidocaine Cream to Boost HRT FocusMedium
Acrux divests US rights for Prilocaine/Lidocaine Cream for $550K to fund HRT development
12 Dec 2025
·ASX Release
·50
Acrux Shareholders Retain Capital Gains Tax Exemptions After Budget ChangesMedium
Acrux Capital Gains Tax Exemptions Unaffected by 2026/27 Federal Budget Changes
14 May 2026
·Regulatory Update
·50
Acrux Advances $0.55M R&D Tax Incentive to Boost Hormone Therapy ProgressMedium
Acrux secures $0.55M advance on FY26 R&D Tax Incentive to support HRT development
12 Mar 2026
·ASX Release
·50
No articles in this tier for the last 12 months.
Market Mentions
7
- appeared in market wrap coverage
These are market wrap articles where Acrux (ASX:ACR) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026
29 Aug 2026
Healthcare Wrap - Week 32 (3 Aug -> 7 Aug) 2026
8 Aug 2026
Healthcare Wrap - Week 31 (27 July -> 31 July) 2026
1 Aug 2026
Healthcare Wrap - Week 22 (25 May -> 29 May) 2026
30 May 2026
Market Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026